AI-generated summary
The authors report a prospective study of 45 patients with early-stage Stargardt disease treated with 650 nm LED photo-biomodulation for one year. Best corrected visual acuity, microperimetry and pattern electroretinography improved after treatment, and PERG changes at 3 and 6 months were associated with later visual acuity gains.
- Participants
- 45
- Who or what was studied
- Patients with Stargardt disease stage 1 (90 eyes of 45 patients) recruited at the University of Bologna
- Wavelengths
- 650 nm
- Limits stated in the abstract
- The abstract reports no control group, and the study is a single-center, prospective case series with a modest sample size.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on dovepress.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 650 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.